RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities.

Product information

CAS Number: 72214-67-6

Molecular Weight: 271.59

Formula: C8H9Cl3N2S

Chemical Name: {[(2,4-dichlorophenyl)methyl]sulfanyl}methanimidamide hydrochloride

Smiles: Cl.NC(=N)SCC1=CC=C(Cl)C=C1Cl

InChiKey: COMNQRICZGJVLE-UHFFFAOYSA-N

InChi: InChI=1S/C8H8Cl2N2S.ClH/c9-6-2-1-5(7(10)3-6)4-13-8(11)12;/h1-3H,4H2,(H3,11,12);1H

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

RRD-251 (10-50 μM; 24 hours) inhibits melanoma growth in-vitro. RRD-251 (50 μM; 2 hours) inhibits Rb-Raf-1 interaction and Rb phosphorylation in non-small cell lung cancer cells. RRD-251 induces apoptosis (50 μM; 18 hours) and cell cycle arrest (20-50 μM; 4 hours). RRD-251 alters the expression of cell cycle and apoptosis regulatory protein.

In Vivo:

RRD-251 (50 mg/kg; i.p.; q.o.d; for 14 days) has anti-cancer activities in vivo on melanomas.

Products are for research use only. Not for human use.